The Encephalopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Encephalopathy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights N

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Encephalopathy and features dormant and discontinued products.

GlobalData tracks 27 drugs in development for Encephalopathy by 27 companies/universities/institutes. The top development phase for Encephalopathy is preclinical with 18 drugs in that stage. The Encephalopathy pipeline has 23 drugs in development by companies and four by universities/ institutes. Some of the companies in the Encephalopathy pipeline products market are: Pfizer, Columbia University and University of Queensland.

The key targets in the Encephalopathy pipeline products market include Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 (Glucose Transporter Type 1 Erythrocyte/Brain or GLUT1 or HepG2 Glucose Transporter or SLC2A1), Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1), and Potassium Channel (KCN).

The key mechanisms of action in the Encephalopathy pipeline product include Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 (Glucose Transporter Type 1 Erythrocyte/Brain or GLUT1 or HepG2 Glucose Transporter or SLC2A1) Activator with two drugs in Preclinical. The Encephalopathy pipeline products include five routes of administration with the top ROA being Intravenous and nine key molecule types in the Encephalopathy pipeline products market including Cell Therapy, and Small Molecule.

Encephalopathy overview

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching, and muscle weakness. Causes include traumas or injuries, genetics, liver disease, hypoxic condition, Lyme disease, and organ failure.

For a complete picture of Encephalopathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.